Outcomes Following Treatment with FOLFOX for Patients with Resectable or Potentially Resectable Metastatic Colorectal...

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Metastatic colorectal cancer (mCRC) treatment often involves chemotherapy.
• Extrahepatic metastases present unique treatment challenges.
• Oxaliplatin is a key chemotherapeutic agent used in mCRC.

Purpose of the Study:

• To evaluate the safety and effectiveness of oxaliplatin-based chemotherapy for mCRC with extrahepatic metastases.
• To compare outcomes of patients with extrahepatic metastases to those with liver-only metastases.

Main Methods:

• Population-based retrospective study in Ontario, Canada.
• Examined perioperative oxaliplatin use for resectable or potentially resectable colorectal metastases.
• Compared outcomes between patients with extrahepatic and liver-only metastases.

Main Results:

• 192 patients had extrahepatic metastases; 70% underwent R0 metastasectomy.
• 3-year disease-free survival was 62% and overall survival was 79%.
• No significant difference in overall survival was observed between liver-only and extrahepatic metastases (lung-only or lung and liver).

Conclusions:

• Oxaliplatin-based chemotherapy is safe for patients with resectable mCRC and extrahepatic metastases.
• Outcomes are comparable to patients with liver-only metastases when appropriately selected.
• This approach supports multidisciplinary treatment recommendations.